Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Wang

Showing results (361-370 of 677) with videos related to

Pageof 68
Sort By:
Leukemia & Lymphoma|May 10, 2021
Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphomaRavi K Goyal, Preetesh Jain, Saurabh P Nagar, et al.
Blood Advances|May 23, 2024
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysisMichael Wang, Tadeusz Robak, Kami J Maddocks, et al.
Journal for Immunotherapy of Cancer|October 17, 2020
Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2Michael Wang, Preetesh Jain, T Linda Chi, et al.
Journal of Pharmaceutical Sciences|December 27, 2022
Improving Dissolution Performance and Drug Loading of Amorphous Dispersions Through a Hierarchical Particle ApproachTze Ning Hiew, Sugandha Saboo, Dmitry Y Zemlyanov, et al.
Haematologica|November 17, 2018
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysisSimon Rule, Martin Dreyling, Andre Goy, et al.
Journal of Hematology & Oncology|December 12, 2013
Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell linesCornel Joseph Phillip, Shadia Zaman, Shujun Shentu, et al.
Oncotarget|September 18, 2014
Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphomaQingqing Cai, Yiming Chen, Dehui Zou, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 2013
Characterization of distinct immunophenotypes across pediatric brain tumor typesAndrea M Griesinger, Diane K Birks, Andrew M Donson, et al.
Science Robotics|May 20, 2026
"Humanoids will soon replace most human workers": A debateHesheng Wang, Michael Wang, Frank Park, et al.
Cancer|September 21, 2004
Colitis in patients with breast carcinoma treated with taxane-based chemotherapyZhiyong Li, Nuhad K Ibrahim, Jay K Wathen, et al.
Pageof 68

Showing results (361-370 of 677) with videos related to

Sort By:
Pageof 68
Leukemia & Lymphoma|May 10, 2021
Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphomaRavi K Goyal, Preetesh Jain, Saurabh P Nagar, et al.
Blood Advances|May 23, 2024
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysisMichael Wang, Tadeusz Robak, Kami J Maddocks, et al.
Journal for Immunotherapy of Cancer|October 17, 2020
Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2Michael Wang, Preetesh Jain, T Linda Chi, et al.
Journal of Pharmaceutical Sciences|December 27, 2022
Improving Dissolution Performance and Drug Loading of Amorphous Dispersions Through a Hierarchical Particle ApproachTze Ning Hiew, Sugandha Saboo, Dmitry Y Zemlyanov, et al.
Haematologica|November 17, 2018
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysisSimon Rule, Martin Dreyling, Andre Goy, et al.
Journal of Hematology & Oncology|December 12, 2013
Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell linesCornel Joseph Phillip, Shadia Zaman, Shujun Shentu, et al.
Oncotarget|September 18, 2014
Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphomaQingqing Cai, Yiming Chen, Dehui Zou, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 2013
Characterization of distinct immunophenotypes across pediatric brain tumor typesAndrea M Griesinger, Diane K Birks, Andrew M Donson, et al.
Science Robotics|May 20, 2026
"Humanoids will soon replace most human workers": A debateHesheng Wang, Michael Wang, Frank Park, et al.
Cancer|September 21, 2004
Colitis in patients with breast carcinoma treated with taxane-based chemotherapyZhiyong Li, Nuhad K Ibrahim, Jay K Wathen, et al.
Pageof 68